ActivBiotics selling assets

ActivBiotics (Lexington, Mass.) said that it is selling its assets. The decision stems from a review of strategic options after the company's rifalazil missed the primary endpoint in a Phase III trial to treat intermittent claudication associated with peripheral arterial disease (PAD) (See BioCentury Extra, Wednesday, Nov. 07, 2007). ...